Buy
Sell
Share Name Share Symbol Market Type Share ISIN Share Description
Glaxosmithkline Plc LSE:GSK London Ordinary Share GB0009252882 ORD 25P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  35.00 2.12% 1,683.60 1,688.80 1,689.60 1,693.20 1,641.00 1,641.00 9,175,512 16:35:05
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 33,754.0 6,221.0 93.9 17.9 84,467

Glaxosmithkline Share Discussion Threads

Showing 21076 to 21099 of 21425 messages
Chat Pages: Latest  845  844  843  842  841  840  839  838  837  836  835  834  Older
DateSubjectAuthorDiscuss
02/4/2020
13:59
Retailers hiked the price of cough and cold medicines by 10.7% last week according to a snapshot analysis of the impact of coronavirus on the economy. Data from the Office for National Statistics (ONS) using online prices set by a number of UK retailers showed the sharp increase for the week ending 29 March compared to the week before.
tradermichael
02/4/2020
13:45
"TraderMichael2 Apr '20 - 11:43 - 21058 of 21063 Which API's exactly?" Presumably the ones India cannot source from China! India has stopped exporting API's as well
crossing_the_rubicon
02/4/2020
13:15
Understand that - just felt given the news about Banks and divis there would be movement this way. Companies like IMB are up which are also defensive
watfordhornet
02/4/2020
13:14
Corona virus is the biggest risk so far.
abdullla
02/4/2020
13:11
Wat GSK is a defensive stock, its a risk on day for any shares. When they fall GSK will go up.
montyhedge
02/4/2020
13:09
Yes it is called market manipulation.
abdullla
02/4/2020
12:12
Is there a reason for drop today - I was expecting this to rise today after the banks cancelled divis etc.
watfordhornet
02/4/2020
11:43
Which API's exactly?
tradermichael
02/4/2020
11:26
Suspect costs have gone up as well Squinty. Particularly for API's, which will be getting scarce for some medicines I'd expect.
crossing_the_rubicon
02/4/2020
11:04
prices. It was mentioned this morning on the news
squintyflinty1
02/4/2020
10:26
Do you mean costs? Or prices?
thamestrader
02/4/2020
10:14
The costs of medicine have gone up sharply across the board which should in turn amplify profitability for Glaxo.
squintyflinty1
01/4/2020
17:54
Positive. "GSK completes divestment of Horlicks" Today GSK also completed the divestment of Horlicks brands rights and other Consumer Healthcare nutrition products to Unilever in other markets for cash proceeds equivalent to £397 million. Through the merger of GSK India with HUL, GSK now holds a 5.7% stake in HUL, an Indian public company listed on the Indian National Stock Exchange (NSE) and Bombay Stock Exchange (BSE). GSK intends to monetise its holding in HUL at such time it considers appropriate, taking into account market conditions. India remains an important growth market for GSK and the company is committed to investing in both its listed Pharmaceuticals business and its OTC and Oral Health brands in this country. As part of the transaction, HUL will distribute these Consumer Healthcare brands, which include market-leading Sensodyne, Crocin, Otrivin and Eno, for GSK in India. GSK will continue to be responsible for demand generation, portfolio strategy, R&D and marketing for these brands. hTTps://www.investegate.co.uk/glaxosmithkline-plc--gsk-/rns/gsk-completes-divestment-of-horlicks/202004011257364358I/ Negative "Ranitidine products to be removed from U.S. market - FDA" The FDA is requesting all manufacturers of ranitidine drugs to withdraw them immediately from the U.S. market due to the presence of an impurity called N-Nitrosodimethylamine (NDMA), a suspected carcinogen. Voluntary recalls started in September 2019. Ranitidine was originally marketed by GlaxoSmithKline (GSK -1.4%) under the brand name Zantac for acid indigestion and heartburn.
crossing_the_rubicon
01/4/2020
16:04
Shell and GSK the safe dividend payers, bank shareholders been shafted by the BOE.
montyhedge
01/4/2020
13:27
Tezcan Gecgil: GlaxoSmithKline One of my top British shares for April is GlaxoSmithKline (LSE: GSK). I believe it may prove to be a defensive portfolio holding if we find ourselves in a global recession. The company reports revenue by three segments: pharmaceuticals, vaccines, and consumer products. Global demand for most of its products are likely to stay stable despite a potential decline in economic conditions. Year-to-date the stock is down about 20%. While the share price has declined to about 1,415p, GSK’s dividend yield has increased — it currently sits at 5.7%. The group pays dividends quarterly and the shares will go ex-dividend on 14 May. I’d consider buying the dip, especially in a Stocks and Shares ISA. Finally, our readers may be interested to know that the group is working on a potential cure (i.e., vaccine) for the novel coronavirus. Tezcan Gecgil does not own shares in GlaxoSmithKline https://tinyurl.com/rux2jnp
igoe104
01/4/2020
11:18
Thought GSK would benefit from Banks stopping dividends. Must be one of safer plays around at moment given variety of productsI seem to keep drip feeding in here at VOD at moment thinking telecoms and pharma better place to be than financials, oil and transport.It is a bit painful
watfordhornet
01/4/2020
03:13
Chartwise in the current climate 1270p looks likely IMO Again That is looking on the bright side If the USA loses control in New York and Hospitals collapse staffwise under the strain ie doctors and nurses acquiring the virus and going sick Then chartwise its 999p IMO
buywell3
31/3/2020
09:44
SNG doing well. Clinical trials.stary yoday in 100 Covid patients
cambourne
31/3/2020
08:11
Trump and J&J seem to be a long way behind the curve?
tradermichael
31/3/2020
07:46
Status of COVID-19 As of 19 March 2020, COVID-19 is no longer considered to be a high consequence infectious diseases (HCID) in the UK. The 4 nations public health HCID group made an interim recommendation in January 2020 to classify COVID-19 as an HCID. This was based on consideration of the UK HCID criteria about the virus and the disease with information available during the early stages of the outbreak. Now that more is known about COVID-19, the public health bodies in the UK have reviewed the most up to date information about COVID-19 against the UK HCID criteria. They have determined that several features have now changed; in particular, more information is available about mortality rates (low overall), and there is now greater clinical awareness and a specific and sensitive laboratory test, the availability of which continues to
johncasey
30/3/2020
18:45
Timelines more realistic if all goes well: "The Trump Administration signed a contract with Johnson & Johnson's pharmaceutical branch. J&J will get $450 million from the government and, combined with its own funding, $1 billion will go to the vaccine development. Already, Moderna has begun trials for its COVI-19 vaccine, but Johnson & Johnson said its own human trials will start by September. It anticipates making one billion doses of the experimental vaccine by 'early 2021,' despite the fact it's only just announced a lead candidate vaccine".
alphorn
26/3/2020
14:34
Resistance and psychology level is 1500p, got to break and hold at close, if they do 1575p here we come.
montyhedge
26/3/2020
14:22
1575p is a given in my book. A couple of decent days all we need.
montyhedge
26/3/2020
14:07
I'm not trusting it either.
patientcapital
Chat Pages: Latest  845  844  843  842  841  840  839  838  837  836  835  834  Older
ADVFN Advertorial
Your Recent History
LSE
GSK
Glaxosmith..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20200528 18:11:31